Harpoon Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>HT</div>
HARP -- USA Stock  

USD 15.90  0.52  3.17%

The next fiscal quarter end is expected on the 30th of September 2020. The stock is currently experiences an active upward rally. Harpoon Therapeutics Issuance Purchase of Equity Shares is very stable at the moment as compared to the past year. Harpoon Therapeutics reported last year Issuance Purchase of Equity Shares of 71.45 Million. As of 21st of August 2020, Share Based Compensation is likely to grow to about 2.2 M, while Free Cash Flow is likely to drop (6.9 M). As many of us are excited about healthcare space, it is fair to recap Harpoon Therapeutics as a unique alternative.
Published over three weeks ago
View all stories for Harpoon Therapeutics | View All Stories
What is September outlook for Harpoon (NASDAQ:HARP)?
Harpoon Therapeutics currently holds 14.37 M in liabilities with Debt to Equity (D/E) ratio of 0.2, which may suggest the entity is not taking enough advantage from borrowing. This firm has a current ratio of 4.39, suggesting that it is liquid enough and is able to pay its financial obligations when due.
Harpoon Therapeutics financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Harpoon Therapeutics, including all of Harpoon Therapeutics's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Harpoon Therapeutics assets, the company is considered highly leveraged. Understanding the composition and structure of overall Harpoon Therapeutics debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.

Understanding Harpoon Total Liabilities

Harpoon Therapeutics liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Harpoon Therapeutics has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Harpoon Therapeutics balance sheet include debt obligations and money owed to different Harpoon Therapeutics vendors, workers, and loan providers. Below is the chart of Harpoon short long-term liabilities accounts currently reported on its balance sheet.
You can use Harpoon Therapeutics financial leverage analysis tool to get a better grip on understanding its financial position

How important is Harpoon Therapeutics's Liquidity

Harpoon Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Harpoon Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Harpoon Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Harpoon Therapeutics's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Harpoon Therapeutics, but it might be worth checking our own buy vs. sell analysis

A Deeper look at Harpoon

The company reported the previous year's revenue of 9.71 M. Net Loss for the year was (55.42 M) with loss before overhead, payroll, taxes, and interest of (35.81 M).

Liabilities Breakdown

18.4 M
Current Liabilities
64.6 M
Long-Term Liabilities
Total Liabilities88.89 Million
Current Liabilities18.4 Million
Long-Term Liabilities64.6 Million

Possible September bounce back of Harpoon?

Recent Information Ratio is up to -0.09. Price may decline again. Harpoon Therapeutics exhibits very low volatility with skewness of 0.78 and kurtosis of 3.43. However, we advise investors to further study Harpoon Therapeutics technical indicators to make sure all market info is available and is reliable.

Our Final Take On Harpoon Therapeutics

Although some other companies in the biotechnology industry are either recovering or due for a correction, Harpoon may not be as strong as the others in terms of longer-term growth potentials. All things considered, as of the 21st of August 2020, our primary 30 days buy-or-sell advice on the firm is Cautious Hold. We believe Harpoon Therapeutics is undervalued with very low odds of distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Harpoon Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com